Dynamic Contrast-Enhanced MRI for Monitoring Antiangiogenic Treatment: Determination of Accurate and Reliable Perfusion Parameters in a Longitudinal Study of a Mouse Xenograft Model.
10.3348/kjr.2013.14.4.589
- Author:
Youngkyu SONG
1
;
Gyunggoo CHO
;
Ji Yeon SUH
;
Chang Kyung LEE
;
Young Ro KIM
;
Yoon Jae KIM
;
Jeong Kon KIM
Author Information
1. Division of Magnetic Resonance, Korea Basic Science Institute, Cheongwon 363-883, Korea. kim.jeongkon@gmail.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Angiogenesis;
Dynamic contrast enhanced MR;
Two compartment model;
Tumor perfusion
- MeSH:
Angiogenesis Inhibitors/therapeutic use;
Animals;
Contrast Media/*diagnostic use;
Female;
Heterografts;
Indoles/*therapeutic use;
Longitudinal Studies;
Magnetic Resonance Imaging/*methods;
Mice;
Mice, Inbred BALB C;
Neoplasm Transplantation;
Neoplasms, Experimental/*diagnosis/drug therapy/pathology;
Pyrroles/*therapeutic use;
Reproducibility of Results;
Tumor Burden
- From:Korean Journal of Radiology
2013;14(4):589-596
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To determine the reliable perfusion parameters in dynamic contrast-enhanced MRI (DCE-MRI) for the monitoring antiangiogenic treatment in mice. MATERIALS AND METHODS: Mice, with U-118 MG tumor, were treated with either saline (n = 3) or antiangiogenic agent (sunitinib, n = 8). Before (day 0) and after (days 2, 8, 15, 25) treatment, DCE examinations using correlations of perfusion parameters (Kep, Kel, and AH from two compartment model; time to peak, initial slope and % enhancement from time-intensity curve analysis) were evaluated. RESULTS: Tumor growth rate was found to be 129% +/- 28 in control group, -33% +/- 11 in four mice with sunitinib-treatment (tumor regression) and 47% +/- 15 in four with sunitinib-treatment (growth retardation). Kep (r = 0.80) and initial slope (r = 0.84) showed strong positive correlation to the initial tumor volume (p < 0.05). In control mice, tumor regression group and growth retardation group animals, Kep (r : 0.75, 0.78, 0.81, 0.69) and initial slope (r : 0.79, 0.65, 0.67, 0.84) showed significant correlation with tumor volume (p < 0.01). In four mice with tumor re-growth, Kep and initial slope increased 20% or greater at earlier (n = 2) than or same periods (n = 2) to when the tumor started to re-grow with 20% or greater growth rate. CONCLUSION: Kep and initial slope may a reliable parameters for monitoring the response of antiangiogenic treatment.
